Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs ...

Terms of the deal were not disclosed in the case, which involved the government’s patents on Gilead’s HIV drugs Truvada and ...

Over the past month, shares of this HIV and hepatitis C drugmaker have returned +1.9%, compared to the Zacks S&P 500 composite's -3.3% change. During this period, the Zacks Medical - Biomedical and ...

Jefferies analyst Michael Yee maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of ...

Situated in Foster City, California, Gilead Sciences, Inc. (GILD) is a top biopharmaceutical company specializing in the ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

Morgan Stanley has recently raised Gilead Sciences Inc (GILD) stock rating, as announced on January 10, 2025, according to Finviz. Earlier, on December 10, 2024, BofA Securities had resumed the stock ...

We recently published a list of 15 Best NASDAQ Dividend Stocks To Buy. In this article, we are going to take a look at where ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Salesforce, Inc. (CRM), Shell plc ...

Gilead Sciences (GILD) partners with LEO Pharma in a $1.7B agreement to develop anti-inflammatory drugs. Read more here.

Gilead Sciences (GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada and ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...